Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site

Cancer Research

Volumn 59, Issue 4, 1999, Pages 911-917

  Halak, Brian K ^a   Maguire Jr , Henry C ^b   Lattime, Edmund C ^a,b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; GAMMA INTERFERON; INTERLEUKIN 10; TRANSPLANTATION ANTIGEN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER SURVIVAL; CARCINOGENICITY; CELLULAR IMMUNITY; CYTOKINE RELEASE; FEMALE; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; FEMALE; H-Y ANTIGEN; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; URINARY BLADDER NEOPLASMS;

EID: 0033557968     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Mosmann, T. R., and Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today, 17: 138-146, 1996.
2. Mosmann, T. R., and Coffman, R. L. Th1 and Th2 cells: differential patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 7: 145-173, 1989.
3. Reiner, S. L., and Locksley, R. M. The regulation of immunity to Leishmania major. Annu. Rev. Immunol., 13: 151-177, 1995.
4. Aruga, A., Aruga, E., Tanigawa, K., Bishop, D. K., Sondak, V. K., and Chang, A. E. Type 1 versus type 2 cytokine release by V β T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol., 159: 664-673, 1997.
5. Lowes, M. A., Bishop, G. A., Crotty, K., St. C. Barneston, R., and Halliday, G. M. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J. Invest. Dermatol., 108: 914-919, 1997.
6. Ding, L., Linsley, P. S., Huang, L.-Y., Germain, R. N., and Shevach, E. M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol., 151: 1224-1234, 1993.
7. de Waal Malefyt, R., Haanen, J., Spits, H., Rocarolo, M.-G., te Velde, A., Figdor, C., Johnson, K., Kastelstein, R., Yssel, H., and de Vries, J. E. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med., 174: 915-924, 1991.
8. Willems, F., Marchant, A., Delville, J.-P., Gerard, C., Delvaux, A., Velu, T., de Boer, M., and Goldman, M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol., 24: 1007-1009, 1994.
9. Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., and O'Garra, A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol., 147: 3815-3822, 1991.
10. + T cell clones and resting T cells: specific inhibition of IL-2 production and proliferation. J. Immunol., 150: 4754-4765, 1993.
11. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (Lond.), 389: 737-742, 1997.
12. Lattime, E. C., Mastrangelo, M. J., Bagasra, O., Li, W., and Berd, D. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol. Immunother., 41: 151-156, 1995.
13. Kruger-Krasagakes, S., Krasagakis, K., Garbe, C., Schmitt, E., Huls, C., Blankenstein, T., and Diamantstein, T. Expression of interleukin-10 in human melanoma. Br. J. Cancer, 70: 1182-1185, 1994.
14. Huang, M., Wang, J., Lee, P., Sharma, S., Mao, J. T., Meissner, H., Uyemura, K., Modlin, R., Wollman, J., and Dubinett, S. M. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res., 55: 3847-3853, 1995.
15. Nakagomi, H., Pisa, P., Pisa, E. K., Yamamoto, Y., Halapi, E., Backlin, K., Juhlin, C., and Kiessling, R. Lack of interleukin-2 (IL-2) expression and selective expression of 1L-10 mRNA in human renal cell carcinoma. Int. J. Cancer, 63: 366-371, 1995.
16. Lattime, E. C., McCue, P. A., Keely, F. X., Li, W., and Gomella, L. G. Expression of IL-10 mRNA in biopsies of superficial and invasive TCC of the human bladder. Proc. Am. Assoc. Cancer Res., 36: 462, 1995.
17. Sato, T., McCue, P., Masuoka, K., Salwen, S., Lattime, E. C., Mastrangelo, M. J., and Berd, D. Interleukin 10 production by human melanoma. Clin. Cancer Res., 2: 1383-1390, 1996.
18. Fortis, C., Foppoli, M., Gianotti, L., Galli, L., Citterio, G., Consogno, G., Gentilini, O., and Braga, M. Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett., 104: 1-5, 1996.
19. Nabioullin, R., Sone, S., Mizuno, K., Yanp, S., Nishioka, Y., Haku, T., and Ogura, T. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J. Leukocyte Biol., 55: 437-442, 1994.
20. + T cell clones inhibit antitumor T cell function by secreting IL-10. J. Immunol., 155: 5719-5727, 1995.
21. Beissert, S., Hosoi, J., Grabbe, S., Asahina, A., and Granstein, R. D. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J. Immunol., 154: 1280-1286, 1995.
22. Allione, A., Consalvo, M., Nanni, P., Lollini, P. L., Cavallo, F., Giovarelli, M., Forni, M., Gulino, A., Colombo, M. P., Dellabona, P., Hock, H., Blankenstein, T., Rosenthal, F. M., Gansbacher, B., Bosco, M. C., Musso, T., Gusella, L., and Forni, G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res., 54: 6022-6026, 1994.
23. Giovarelli, M., Musiani, P., Modesti, A., Dellabona, P., Casorati, G., Allione, A., Consalvo, M., Cavallo, F., di Pierro, F., De Giovanni, C., Musso, T., and Forni, G. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol., 155: 3112-3123, 1995.
24. Kundu, N., Beaty, T. L., Jackson, M. J., and Fulton, A. M. Antimetastatic and antitumor activities of interleukin-10 in a murine model of breast cancer. J. Natl. Cancer Inst. (Bethesda), 88: 536-541, 1996.
25. Gerard, C. M., Bruyns, C., Delvaux, A., Baudson, N., Dargent, J.-L., Goldman, M., and Velu, T. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum. Gene Ther., 7: 23-31. 1996.
26. Summerhayes, I. C., and Franks, L. M. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J. Natl. Cancer Inst. (Bethesda). 62: 1017-1023, 1979.
27. Scott, D. M., Ehrmann, I. E., Ellis, P. S., Chandler, P. R., and Simpson, E. Why do some females reject males? The molecular basis for male-specific graft rejection. J. Mol. Med., 75: 103-114, 1997.
28. b epitope is encoded by a novel mouse Y chromosome gene. Nat. Genet., 14: 474-478, 1996.
29. Rosenberg, A. S., Mizuochi, T., Sharrow, S. O., and Singer, A. Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. J. Exp. Med., 165: 1296-1315, 1987.
30. Monken, C. E., Gomella, L. G., Li, W., Fink, E., and Lattime, E. C. IL-10 is produced by human transitional cell carcinoma lines immortalized by retroviral transfection with human papilloma virus E6/E7 genes. Proc. Am. Assoc. Cancer Res., 37: 451, 1996.
31. 2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol., 157: 5512-5520, 1996.
32. Maeda. H., Kuwahara, H., Ichimura, Y., Ohtsuki, M., Kurakata, S., and Shiraishi, A. TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J. Immunol., 155: 4926-4932, 1995.
33. + Th1-like responses. J. Clin. Invest., 98: 1010-1020, 1996.
34. Rennick, D., Davidson, N., and Berg, D. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin. Immunol. Immunopathol., 76: S174-S178, 1995.
35. Brubaker, J. O., Thompson, C. M., Morrison, L. M., Knipe, D. M., Siber, G. R., and Finberg, R. W. Th1-associated immune responses to β-galactosidase expressed by a replication-defective herpes simplex virus. J. Immunol., 157: 1598-1604, 1996.
36. Yamamura, M., Uyemura, K., Deans, R. J., Weinberg, K., Rea, T. H., Bloom, B. R., and Modlin, R. L. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science (Washington DC), 254: 277-279, 1991.
37. Qin, Z., Noffz, G., Mohaupt, M., and Blankenstein, T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol., 159: 770-776, 1997.
38. Richter, G., Kruger-Krasagakes, S., Hein, G., Huls, C., Schmitt, E., Diamantstein, T., and Blankenstein, T. Interleukin-10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res., 53: 4134-4137, 1993.
39. Steinbrink, K., Wölfl, M., Jonuleit, H., Knop, J., and Enk, A. H. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol., 159: 4772-4780, 1997.
40. Donawho, C. K., Bucana, C. D., and Kripke, M. L. Enhanced growth of murine melanomas by local UV-B radiation is dependent on interleukin-10. Proc. Am. Assoc. Cancer Res., 36: A2832, 1995.
41. Hagenbaugh, A., Sharma, S., Dubinett, S. M., Sherry, H.-Y. W., Aranda, R., Cheroutre, H., Fowell, D. J., Binder, S., Tsao, B., Locksley, R. M., Moore, K. W., and Kronenberg, M. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med., 185: 2101-2110, 1997.
42. Mastrangelo, M. J., Bellet, R. F., Berkelhammer, J., and Clark, W. H. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer (Phila.), 36: 1305-1308, 1975.
43. Lattime, E. C., Lee, S. S., Eisenlohr, L. C., and Mastrangelo, M. M. In situ gene transfection using vaccinia virus vectors. Semin. Oncol., 23: 88-100, 1996.
44. Mastrangelo, M. J., Maguire, H. C., Jr., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., and Lattime, E. C. Intratumoral recombinant GM-CSF encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther., in press, 1999.